Objective: To evaluate the role of vascular endothelial growth factor (VEGF) plasmid DNA (pDNA) in improving flap revascularization in a previously developed rat model. Our hypothesis was that the uptake and expression of VEGF pDNA in the wound bed would improve revascularization and flap viability.
R
ECONSTRUCTION AFTER SALvage surgery for failed radiation or chemoradiation often involves free-tissue transfer and provides a challenge for the surgeon because of the effects of radiation on the host microvasculature. These changes ultimately affect wound healing. Whereas reconstructive flaps may have adequate blood supply to survive, the radiation effects on the host wound bed may delay flap incorporation and revascularization between the flap and host tissue. The effects of radiation therapy on the microvasculature have been described as a decrease in capillary density and diameter as well as excessive fibrosis, endothelial cell damage, and reduced cellular turnover. [1] [2] [3] Vascular endothelial growth factor (VEGF) is a potent angiogenic cytokine that induces angiogenesis, stimulates endothelial cells to mitogenic responses, and increases microvascular permeability. 4 In the skin, VEGF is secreted by keratinocytes and fibroblasts and is especially active on dermal vascular structures. 5 Previously, 2 of us have shown that the topical application of fibrin-embedded VEGF protein enhanced survival of fasciocutaneous flaps in nonirradiated animals. 6 Other investigators have also demonstrated improved skin flap survival using VEGF gene therapy in nonirradiated animals. 7, 8 No previous studies, to our knowledge, have examined the effects of VEGF on flap revascularization in previously irradiated animals. The purpose of this study was to evaluate the effects of topical VEGF pDNA on revascularization of a ventral fasciocutaneous flap in an irradiated rat model.
METHODS
After Institutional Animal Care and Use Committee review and approval, 28 male SpragueDawley rats (Charles River Laboratories International Inc, Wilmington, Massachusetts) received a total dose of 40 Gy electron beam radiation to the ventral abdominal wall. After a 1-month recovery period, the rats underwent a ventral fasciocutaneous flap procedure with a 2-hour ischemia period. The rats were initially divided into 2 groups, an experi- mental arm to receive VEGF pDNA and a control arm to receive only carriers (Figure 1) . The experimental group (n=14) received topical VEGF pDNA, in vivo cationic polymer (jetPEI; Polyplus-transfection Inc, New York, New York), and fibrin sealant (Tisseel; Baxter International Inc, Deerfield, Illinois). The control group (n=14) received topical cationic polymer and fibrin sealant only. To evaluate the time course of revascularization, 7 rats from each group underwent pedicle ligation at 8 or 14 days. The primary outcome measure was percentage of flap revascularization measured as area of viable skin 5 days after pedicle ligation.
RADIATION PROTOCOL
All rats underwent general anesthesia using isoflurane inhalation during radiation. A lead shield was placed to isolate the templated flap region. A 6-MeV electron beam accelerator (Clinac 2100EX; Varian Medical Systems Inc, Palo Alto, California) was used to irradiate the rats. A bolus material of 2 cm on top of the abdomen was used to improve radiation dose distribution. During a 10-day period, radiation was administered in 5 divided doses of 8 cGy each, totaling 40 Gy.
VENTRAL FASCIOCUTANEOUS FLAP PROCEDURE
After a recovery period of 28 days after radiation, the rats underwent a ventral fasciocutaneous flap procedure. A ventral 3ϫ6-cm fasciocutaneous flap (Figure 2A ) pedicled on the inferior epigastric artery and vein was raised. Following elevation of the flap, a 20-g temporary occlusion clip was applied to the vascular pedicle for 2 hours to simulate the ischemic period during free-tissue transfer ( Figure 2B ). Prior to flap inset and closure, experimental or control solution was applied topically ( Figure 2C ). During this period, the flap was inset ( Figure 2D ) and the rats were awakened from anesthesia. At the end of the 2-hour period of simulated ischemia, the rats were briefly reanesthetized, the corner of the flap was elevated, the occlusion clip was removed, and the wound was reapproximated. The rats were monitored daily for signs of pain and discomfort and treated with analgesics as needed. They then underwent ligation of the inferior epigastric vein and artery at the previously outlined intervals.
VEGF pDNA AND CARRIERS
Preparation of VEGF pDNA was performed using recombinant polymerase chain reaction technology similar to that previously described. 9 The messenger RNA (mRNA) of VEGF with alternate splicing amino acid number 165 (VEGF 165 ) was isolated from U937 histiocytic lymphoma cells (ATCC CRL-1593). Complementary DNA (cDNA) was synthesized from 1-µg polyadenylated RNA by a cDNA synthesis kit (Pharmacia Corporation, Kalamazoo, Michigan). cDNA application via polymerase chain reaction occurred using the VEGF 165 -specific primers: Forward: 5ЈGAAACCATGAACTTTCT-GCTG and Reverse: 5ЈTCACCGCCTCGGCTTGTCACA.
This encodes the entire region and includes the signal sequence. The polymerase chain reaction product was ligated to pCEF1␣-DNT-IgSP with the Eukaryotic TA Cloning KitUnidirectional (Invitrogen, Carlsbad, CA). The ligation mixture was transformed, colonies were selected, and the mixture was sequenced from both directions to ensure appropriate cDNA sequencing (Figure 3) . For the present studies, the pDNA expressing the VEGF 165 was purified via Qiagen Plasmid Maxi Kits (Qiagen Inc, Valencia, California), and aliquots were nicked at appropriate restriction sites and run on 1% agarose gels for quality assurance. After the vascular clip was applied, the rats were given 1 of 2 treatments. The control group was treated with a buffered solution in a polycation complex (in vivo cationic polymer) and further suspended in fibrin sealant. The experimental group received 100 µg of pDNA-expressing, VEGF-condensed cationic polymer and further suspended in fibrin sealant. One milliliter of the viscous solutions was evenly distributed over the exterior surface of the 3ϫ6-cm elevated flap.
EVALUATION OF FLAP REVASCULARIZATION
Percentage of flap viability was evaluated on postligation procedure day 5 as a marker for flap revascularization. Viable flap area was characterized by warm, pink, hair-bearing skin. Nonviable flap area was characterized by dry, hard, hairless eschar. The rats were given general anesthesia, and standardized digital photographs of the ventral flap were taken. Three qualified masked observers were used to delineate viable and nonviable areas by tracing template etchings. Then, cutouts of viable tissue from the template were weighed to express a percentage of the total template weight, which effectively gave the area percentage of viable flap tissue. Rats were excluded for evaluation if they developed a clinically significant hematoma, seroma, or infection.
STATISTICAL ANALYSIS
To determine the number of rats needed, a power analysis was performed using our preliminary data; it indicated that a minimum of 6 rats for each group would be required to complete a meaningful statistical analysis of flap revascularization to obtain PϽ.05 of significance. A Mann-Whitney test was used to evaluate whether a difference in percentage of flap viability existed between the experimental and control groups at 8 and 14 days to pedicle ligation.
RESULTS
We observed varying degrees of revascularization between the 4 groups, with a trend toward increased re- vascularization in the 2 groups with longer duration to pedicle ligation (Figure 4) . Rats receiving VEGF pDNA had a significantly higher rate of flap revascularization (90.8% vs 79.8%) after pedicle ligation at 14 days (P=.045). At 8 days, rats receiving VEGF pDNA (group 1) had an increased rate of flap revascularization (58.2% vs 42.8%) that approached significance (P=.11). One rat from each of the 4 groups developed a seroma, and those rats were excluded from analysis.
COMMENT
Microvascular reconstruction after salvage surgery for failed radiation or chemoradiation is a difficult challenge. The long-term viability and healing of a reconstructive flap is not only dependent on the vascular pedicle but also on revascularization from the surrounding host tissue. It has been shown that previous radiation therapy leads to microvascular compromise in the host tissue that manifests as excessive fibrosis, endothelial cell damage, and reduced cellular turnover. 1, 3 Because of these effects on the host tissue, revascularization between an irradiated wound bed and a reconstructive flap may be diminished.
Vascular endothelial growth factor is an attractive agent for potential therapeutic application because it may improve the microvasculature in previously irradiated tissue and, in turn, the revascularization of remote flap tissue. Several previous studies have evaluated the effects of exogenous VEGF application on skin graft survival. 4, 7, 8, [10] [11] [12] [13] These studies include evaluation of local and systemic application of VEGF protein or VEGF pDNA in various vectors. In a previous study, 2 of us 6 evaluated the ability of topical application of fibrinembedded VEGF pDNA and VEGF protein to enhance revascularization and survival of fasciocutaneous flaps in nonirradiated animals. We found that the use of a geneactivated matrix, consisting of pDNA entrapped in a polymer matrix carrier, was an effective method for gene transfer. Studies have shown that matrix carriers serve as a scaffold to hold DNA in situ until endogenous fibroblasts arrive. 14, 15 Other studies have also shown that fibrinembedded administration of VEGF pDNA does not influence its angiogenic properties but enhances skin flap survival. 8, 16 In the present study, we have shown that topical application of VEGF pDNA significantly improves revascularization of a ventral fasciocutaneous flap in an irradiated rat model after pedicle ligation at 14 days postoperatively. At 8 days postoperatively, we found that VEGF pDNA application did not lead to significantly increased revascularization and flap viability.
Very few previous studies, to our knowledge, have evaluated the effects of VEGF in an irradiated field. In a study of skin graft survival in irradiated rats, Richter et al 17 evaluated the effect of local application of VEGF protein. They found that exogenously administered VEGF significantly decreased the graft failure rate but microvascular density was not different between groups. The lack of effect on microvascular density may be due to an increase in newly formed vessels in the recipient bed and not in the transplant bed. Previous studies have also shown similar findings of improved graft survival without a change in vessel density in the transplanted tissue. 12, 13, 18, 19 The potential clinical application of this study involves the exogenous use of naturally occurring growth factors and cytokines to augment the protracted wound healing and revascularization of reconstructive flaps in previously irradiated patients. Promising results in soft tissue wound healing may translate into healing in microvascular reconstruction of bone (such as that of the mandible), and further studies are needed for these types of applications. The limitations of this study include a small number of rats in each group; the time between radiation and surgery, which may vary clinically; and the fact that the flap and tissue bed have been irradiated. Typically, the reconstructive flap is taken from a nonirradiated field and brings a fresh blood supply to the wound bed. In this model, previous radiation may affect the revascularization potential of the flap. It will be interesting to see whether future studies demonstrate a change in microvascular density or VEGF mRNA expression in this previously irradiated flap. Long-term studies are needed regarding the potential neoplastic effects or neoplasia potentiating effects of using VEGF gene therapy in a previously cancer-laden wound bed. 
